Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1131-1138

  Darnell, Malin ^a,d   Schreiter, Thomas ^b   Zeilinger, Katrin ^b   Urbaniak, Thomas ^b   Söderdahl, Therese ^a   Rossberg, Ingrid ^b   Dillnér, Birgitta ^a   Berg, Anna Lena ^a   Gerlach, Jörg C ^c   Andersson, Tommy B ^a,d  

^a ASTRAZENECA R AND D   (Sweden)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUPROPION HYDROXYLASE; CARRIER PROTEIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; KETOCONAZOLE; MIDAZOLAM; OXYGENASE; PHENACETIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ARTICLE; BIOREACTOR; CELL POLARITY; CELL PROLIFERATION; CELL STRAIN HEPARG; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAHEPATIC BILE DUCT; LIVER CELL; LIVER METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; THREE DIMENSIONAL MULTICOMPARTMENT CAPILLARY MEMBRANE BIOREACTOR;

BIOREACTORS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; SUBSTRATE SPECIFICITY;

EID: 79959412031     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037721     Document Type: Article

References (33)

1. Abadie-Viollon C, Martin H, Blanchard N, Pekthong D, Bachellier P, Mantion G, Heyd B, Schuler F, Coassolo P, Alexandre E, et al. (2010) Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions. Toxicol In Vitro 24:346-356.
2. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83. (Pubitemid 43042648)
3. Chao P, Maguire T, Novik E, Cheng KC, and Yarmush ML (2009) Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol 78:625-632.
4. De Bartolo L, Salerno S, Morelli S, Giorno L, Rende M, Memoli B, Procino A, Andreucci VE, Bader A, and Drioli E (2006) Long-term maintenance of human hepatocytes in oxygen-permeable membrane bioreactor. Biomaterials 27:4794-4803. (Pubitemid 43849982)
5. Fahmi OA, Kish M, Boldt S, and Obach RS (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605-1611.
6. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606. (Pubitemid 37311146)
7. Gerlach JC, Encke J, Hole O, Müller C, Ryan CJ, and Neuhaus P (1994) Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation 58:984-988. (Pubitemid 24356468)
8. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, and Hall SD (2004) The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75:89-100. (Pubitemid 38130121)
9. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, and Guguen-Guillouzo C (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico-Biol Interact 168:66-73. (Pubitemid 46659919)
10. Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D, and Zhong XB (2010) A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 38:988-994.
11. Kanebratt KP and Andersson TB (2008a) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452. (Pubitemid 351929328)
12. Kanebratt KP and Andersson TB (2008b) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137-145.
13. Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, and Bertilsson L (2008c) Cytochrome P450 induction by rifampicin in healthy subjects: determination by the Karolinska cocktail and the endogenous marker for 4beta-hydroxycholesterol. Clin Pharmacol Ther 84:589-594.
14. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2004) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466. (Pubitemid 39469869)
15. Kharasch ED, Mitchell D, and Coles R (2008) Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 48:464-474. (Pubitemid 351389115)
16. Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, et al. (2008) Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 36:851-862. (Pubitemid 351574882)
17. Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, and McLeod J (2009) Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 31:286-298.
18. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975. (Pubitemid 44837757)
19. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, and Fardel O (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
20. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, and McLachlan AJ (2006) Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75-84. (Pubitemid 43964914)
21. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804. (Pubitemid 34671092)
22. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431. (Pubitemid 36378519)
23. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gómez-Lechón MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520.
24. Schmelzer E, Mutig K, Schrade P, Bachmann S, Gerlach JC, and Zeilinger K (2009) Effect of human patient plasma ex vivo treatment on gene expression and progenitor cell activation of primary human liver cells in multi-compartment 3D perfusion bioreactors for extra-corporeal liver support. Biotechnol Bioeng 103:817-827.
25. Tham LS, Lee HS, Wang L, Yong WP, Fan L, Ong AB, Sukri N, Soo R, Lee SC, and Goh BC (2006) Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Ther Drug Monit 28:255-261. (Pubitemid 44314958)
26. Toepke MW and Beebe DJ (2006) PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip 6:1484-1486. (Pubitemid 46100743)
27. Tsunoda SM, Velez RL, von Moltke LL, and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
28. Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, and Pelkonen O (2009) Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 23:748-753.
29. Yong WP, Wang LZ, Tham LS, Wong CI, Lee SC, Soo R, Sukri N, Lee HS, and Goh BC (2008) A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemother Pharmacol 62:243-251. (Pubitemid 351692080)
30. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, et al. (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104-112.
31. Zeilinger K, Holland G, Sauer IM, Efimova E, Kardassis D, Obermayer N, Liu M, Neuhaus P, and Gerlach JC (2004) Time course of primary liver cell reorganization in three-dimensional high-density bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study. Tissue Eng 10:1113-1124. (Pubitemid 39223790)
32. Zeilinger K, Sauer IM, Pless G, Strobel C, Rudzitis J, Wang A, Nüssler AK, Grebe A, Mao L, Auth SH, et al. (2002) Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions. Altern Lab Anim 30:525-538. (Pubitemid 35283188)
33. Zeilinger K, Schreiter T, Darnell M, Soderdahl T, Lubberstedt M, Dillner B, Knobeloch D, Nussler AK, Gerlach JC, and Andersson TB (2011) Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng Part C Methods 17:549-556.